RSV mucosal vaccine
US9463236B2 · kind B2 · utility
0Cited by
4References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2012 |
| Grant date | Oct 11, 2016 |
| Priority date | — |
| Expiry date | Nov 24, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18551
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.